Company news

KYORIN Pharmaceutical Co.,Ltd. news in 2026

KYORIN Pharmaceutical Co.,Ltd.'s news releases, calls and decks from 2026, newest first.

View company

KYORIN and Acadia Pharmaceuticals Enter into Distribution Agreement for DAYBUE STIX (Trofinetide) for Rett Syndrome in Japan

November 16, 2026

[Summary]Consolidated Financial Results for the Six Months Ended September 30, 2026 [Japanese GAAP]

November 9, 2026

Notice Regarding Difference Between Financial Forecast and Actual Results and Revision

November 9, 2026

KYORIN and Edesa Biotech Enter into License Agreement for EB05 for ARDS (Acute Respiratory Distress Syndrome)

November 9, 2026

Consolidated Financial Results for Second Quarter of FY2026 - Supplementary Information

November 9, 2026

Notice Concerning Change in Major Shareholder

October 28, 2026

(Update on Disclosed Matter) Notice Regarding Transfer of Generic Drug Business

September 30, 2026

KYORIN to Commence Promotion Activities for Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5%

August 3, 2026

[Summary]Consolidated Financial Results for the Three Months Ended June 30, 2026 [Japanese GAAP]

July 30, 2026

KYORIN Entered into Joint Marketing Agreement in Japan for Allergic Conjunctivitis Treatment Alesion Eyelid Cream 0.5%

July 13, 2026

KYORIN Pharmaceutical: Operating profit fell 71.6% year-over-year as sales declined and R&D costs rose

May 12, 2026

Kyorin Pharmaceutical Co Ltd - Kyorin Enters Into License Agreement With Biodol For Novel Neuropathic Pain Treatment

March 31, 2026

TABLE-Kyorin Pharmaceutical - 9-MTH group results

February 4, 2026

KYORIN Pharmaceutical: Strong nine-month results, but full-year outlook projects lower sales and profits

February 3, 2026

Decks in 2026